{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:11:42Z","timestamp":1792721502593,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,8,5]],"date-time":"2008-08-05T00:00:00Z","timestamp":1217894400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s11060-008-9662-x","type":"journal-article","created":{"date-parts":[[2008,8,4]],"date-time":"2008-08-04T12:50:22Z","timestamp":1217854222000},"page":"309-314","source":"Crossref","is-referenced-by-count":47,"title":["Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma"],"prefix":"10.1007","volume":"90","author":[{"given":"Johannes E. A.","family":"Wolff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Kramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf-Dieter","family":"Kortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Pietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Jorch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Gnekow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Hern\u00e1iz","family":"Driever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,8,5]]},"reference":[{"key":"9662_CR1","first-page":"55","volume":"12","author":"JW Lance","year":"1975","unstructured":"Lance JW, Anthony M (1975) Sodium valproate in the management of intractable epilepsy: comparison with clonazepam. Proc Aust Assoc Neurol 12:55\u201360","journal-title":"Proc Aust Assoc Neurol"},{"issue":"Suppl 2","key":"9662_CR2","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1111\/j.1528-1157.1983.tb04652.x","volume":"24","author":"RM Post","year":"1983","unstructured":"Post RM, Uhde TW (1983) Treatment of mood disorders with antiepileptic medications: clinical and theoretical implications. Epilepsia 24(Suppl 2):S97\u2013S108. doi: 10.1111\/j.1528-1157.1983.tb04652.x","journal-title":"Epilepsia"},{"key":"9662_CR3","first-page":"208","volume":"14","author":"M Anthony","year":"1977","unstructured":"Anthony M, Hinterberger H, Lance JW (1977) Plasma sodium valproate levels and clinical response in epilepsy. Clin Exp Neurol 14:208\u2013215","journal-title":"Clin Exp Neurol"},{"key":"9662_CR4","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1528-1167.2007.00989.x","volume":"48","author":"NA Limdi","year":"2007","unstructured":"Limdi NA, Knowlton RK, Cofield SS, Ver Hoef LW, Paige AL, Dutta S et al (2007) Safety of rapid intravenous loading of valproate. Epilepsia 48:478\u2013483. doi: 10.1111\/j.1528-1167.2007.00989.x","journal-title":"Epilepsia"},{"key":"9662_CR5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(80)91159-9","volume":"1","author":"NA Brown","year":"1980","unstructured":"Brown NA, Kao J, Fabro S (1980) Teratogenic potential of valproic acid. Lancet 1:660\u2013661. doi: 10.1016\/S0140-6736(80)91159-9","journal-title":"Lancet"},{"key":"9662_CR6","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJM199311043291904","volume":"329","author":"JI Isojarvi","year":"1993","unstructured":"Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV (1993) Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 329:1383\u20131388. doi: 10.1056\/NEJM199311043291904","journal-title":"N Engl J Med"},{"key":"9662_CR7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/0006-8993(85)90207-0","volume":"347","author":"CM Regan","year":"1985","unstructured":"Regan CM (1985) Therapeutic levels of sodium valproate inhibit mitotic indices in cells of neural origin. Brain Res 347:394\u2013398. doi: 10.1016\/0006-8993(85)90207-0","journal-title":"Brain Res"},{"key":"9662_CR8","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood.V90.2.891","volume":"90","author":"R Selby","year":"1997","unstructured":"Selby R, Nisbet-Brown E, Basran RK, Chang L, Olivieri NF (1997) Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease. Blood 90:891\u2013893","journal-title":"Blood"},{"key":"9662_CR9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/08880010390158496","volume":"20","author":"M Kieslich","year":"2003","unstructured":"Kieslich M, Schwabe D, Cinatl J Jr, Driever PH (2003) Increase of fetal hemoglobin synthesis indicating differentiation induction in children receiving valproic acid. Pediatr Hematol Oncol 20:15\u201322. doi: 10.1080\/713842215","journal-title":"Pediatr Hematol Oncol"},{"key":"9662_CR10","first-page":"3585","volume":"18","author":"MM Knupfer","year":"1998","unstructured":"Knupfer MM, Hernaiz-Driever P, Poppenborg H, Wolff JE, Cinatl J (1998) Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro. Anticancer Res 18:3585\u20133589","journal-title":"Anticancer Res"},{"key":"9662_CR11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1055\/s-2008-1043809","volume":"211","author":"PH Driever","year":"1999","unstructured":"Driever PH, Knupfer MM, Cinatl J, Wolff JE (1999) Valproic acid for the treatment of pediatric malignant glioma. Klin Padiatr 211:323\u2013328","journal-title":"Klin Padiatr"},{"key":"9662_CR12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/pbc.20083","volume":"43","author":"O Witt","year":"2004","unstructured":"Witt O, Schweigerer L, Driever PH, Wolff J, Pekrun A (2004) Valproic acid treatment of glioblastoma multiforme in a child. Pediatr Blood Cancer 43:181. doi: 10.1002\/pbc.20083","journal-title":"Pediatr Blood Cancer"},{"key":"9662_CR13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/08880010490514985","volume":"21","author":"PH Driever","year":"2004","unstructured":"Driever PH, Wagner S, Hofstadter F, Wolff JE (2004) Valproic acid induces differentiation of a supratentorial primitive neuroectodermal tumor. Pediatr Hematol Oncol 21:743\u2013751. doi: 10.1080\/08880010490514985","journal-title":"Pediatr Hematol Oncol"},{"key":"9662_CR14","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","volume":"276","author":"CJ Phiel","year":"2001","unstructured":"Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734\u201336741. doi: 10.1074\/jbc.M101287200","journal-title":"J Biol Chem"},{"key":"9662_CR15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","volume":"85","author":"CM Das","year":"2007","unstructured":"Das CM, Aguilera D, Vasquez H, Prasad P, Zhang M, Wolff JE et al (2007) Valproic acid induces p21 and topoisomerase-II (alpha\/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 85:159\u2013170. doi: 10.1007\/s11060-007-9402-7","journal-title":"J Neurooncol"},{"key":"9662_CR16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/med.20027","volume":"25","author":"RA Blaheta","year":"2005","unstructured":"Blaheta RA, Michaelis M, Driever PH, Cinatl J Jr (2005) Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 25:383\u2013397. doi: 10.1002\/med.20027","journal-title":"Med Res Rev"},{"key":"9662_CR17","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1124\/jpet.108.137398","volume":"325","author":"G Dong","year":"2008","unstructured":"Dong G, Wang L, Wang CY, Yang T, Kumar MV, Dong Z (2008) Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents. J Pharmacol Exp Ther 325:978\u2013984. doi: 10.1124\/jpet.108.137398","journal-title":"J Pharmacol Exp Ther"},{"key":"9662_CR18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.transproceed.2008.01.039","volume":"40","author":"J Johnson","year":"2008","unstructured":"Johnson J, Pahuja A, Graham M, Hering B, Hancock WW, Bansal-Pakala P (2008) Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+ regulatory T cells in rhesus macaques. Transplant Proc 40:459\u2013461. doi: 10.1016\/j.transproceed.2008.01.039","journal-title":"Transplant Proc"},{"key":"9662_CR19","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/sj.onc.1203963","volume":"19","author":"L Huang","year":"2000","unstructured":"Huang L, Sowa Y, Sakai T, Pardee AB (2000) Activation of the p21WAF1\/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19:5712\u20135719. doi: 10.1038\/sj.onc.1203963","journal-title":"Oncogene"},{"key":"9662_CR20","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.bcp.2007.10.035","volume":"75","author":"X Yi","year":"2008","unstructured":"Yi X, Wei W, Wang SY, Du ZY, Xu YJ, Yu XD (2008) Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling. Biochem Pharmacol 75:1697\u20131705. doi: 10.1016\/j.bcp. 2007.10.035","journal-title":"Biochem Pharmacol"},{"key":"9662_CR21","doi-asserted-by":"crossref","unstructured":"Domingo-Dom\u00e8nech J, Pippa R, T\u00e1pia M, Gasc\u00f3n P, Bachs O, Bosch M (2008) Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat (in press)","DOI":"10.1007\/s10549-007-9837-8"},{"key":"9662_CR22","first-page":"177","volume":"32","author":"D Carlisi","year":"2008","unstructured":"Carlisi D, Vassallo B, Lauricella M, Emanuele S, D\u2019Anneo A, Di Leonardo E et al (2008) Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. Int J Oncol 32:177\u2013184","journal-title":"Int J Oncol"},{"key":"9662_CR23","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1158\/1535-7163.MCT-07-2347","volume":"7","author":"CA Hassig","year":"2008","unstructured":"Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, Wash PL et al (2008) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7:1054\u20131065. doi: 10.1158\/1535-7163.MCT-07-2347","journal-title":"Mol Cancer Ther"},{"key":"9662_CR24","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1535-7163.MCT-07-2026","volume":"7","author":"M Fournel","year":"2008","unstructured":"Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A et al (2008) MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7:759\u2013768. doi: 10.1158\/1535-7163.MCT-07-2026","journal-title":"Mol Cancer Ther"},{"key":"9662_CR25","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ejca.2008.01.023","volume":"44","author":"A Petrella","year":"2008","unstructured":"Petrella A, D\u2019Acunto CW, Rodriquez M, Festa M, Tosco A, Bruno I et al (2008) Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1. Eur J Cancer 44:740\u2013749. doi: 10.1016\/j.ejca.2008.01.023","journal-title":"Eur J Cancer"},{"key":"9662_CR26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11060-007-9505-1","volume":"87","author":"SE Spiller","year":"2008","unstructured":"Spiller SE, Ditzler SH, Pullar BJ, Olson JM (2008) Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J Neurooncol 87:133\u2013141. doi: 10.1007\/s11060-007-9505-1","journal-title":"J Neurooncol"},{"key":"9662_CR27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10637-007-9075-2","volume":"26","author":"GR Blumenschein Jr","year":"2008","unstructured":"Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL et al (2008) Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and\/or metastatic head and neck cancer. Invest New Drugs 26:81\u201387. doi: 10.1007\/s10637-007-9075-2","journal-title":"Invest New Drugs"},{"key":"9662_CR28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.bjc.6603851","volume":"97","author":"A Atmaca","year":"2007","unstructured":"Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B et al (2007) Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 97:177\u2013182. doi: 10.1038\/sj.bjc.6603851","journal-title":"Br J Cancer"},{"key":"9662_CR29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1055\/s-2008-1046473","volume":"208","author":"JE Wolff","year":"1996","unstructured":"Wolff JE, Boos J, Kuhl J (1996) HIT-GBM: multicenter study of treatment of children with malignant glioma. Klin Padiatr 208:193\u2013196","journal-title":"Klin Padiatr"},{"key":"9662_CR30","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s002800050586","volume":"39","author":"E Bouffet","year":"1997","unstructured":"Bouffet E, Khelfaoui F, Philip I, Biron P, Brunat-Mentigny M, Philip T (1997) High-dose carmustine for high-grade gliomas in childhood. Cancer Chemother Pharmacol 39:376\u2013379. doi: 10.1007\/s002800050586","journal-title":"Cancer Chemother Pharmacol"},{"key":"9662_CR31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/bjc.1998.555","volume":"78","author":"EJ Estlin","year":"1998","unstructured":"Estlin EJ, Lashford L, Ablett S, Price L, Gowing R, Gholkar A et al (1998) Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children\u2019s Cancer Study Group. Br J Cancer 78:652\u2013661","journal-title":"Br J Cancer"},{"key":"9662_CR32","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/mpo.1215","volume":"37","author":"L Liu","year":"2001","unstructured":"Liu L, Vapiwala N, Munoz LK, Winick NJ, Weitman S, Strauss LC et al (2001) A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors. Med Pediatr Oncol 37:390\u2013392. doi: 10.1002\/mpo.1215","journal-title":"Med Pediatr Oncol"},{"key":"9662_CR33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1634\/theoncologist.9-2-197","volume":"9","author":"A Broniscer","year":"2004","unstructured":"Broniscer A, Gajjar A (2004) Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist 9:197\u2013206. doi: 10.1634\/theoncologist.9-2-197","journal-title":"Oncologist"},{"key":"9662_CR34","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1200\/JCO.2005.04.6599","volume":"24","author":"SS Donaldson","year":"2006","unstructured":"Donaldson SS, Laningham F, Fisher PG (2006) Advances toward an understanding of brainstem gliomas. J Clin Oncol 24:1266\u20131272. doi: 10.1200\/JCO.2005.04.6599","journal-title":"J Clin Oncol"},{"key":"9662_CR35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00165101","volume":"7","author":"R Sposto","year":"1989","unstructured":"Sposto R, Ertel IJ, Jenkin RD, Boesel CP, Venes JL, Ortega JA et al (1989) The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol 7:165\u2013177. doi: 10.1007\/BF00165101","journal-title":"J Neurooncol"},{"key":"9662_CR36","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. doi: 10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"9662_CR37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1055\/s-2008-1046472","volume":"208","author":"JE Wolff","year":"1996","unstructured":"Wolff JE, Boos J, Krahling KH, Jurgens H (1996) Second temporal remission in a malignant glioma with trofosfamide and etoposide: a case report. Klin Padiatr 208:190\u2013192","journal-title":"Klin Padiatr"},{"key":"9662_CR38","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/1097-0142(20001115)89:10<2131::AID-CNCR14>3.0.CO;2-J","volume":"89","author":"JE Wolff","year":"2000","unstructured":"Wolff JE, Molenkamp G, Westphal S, Pietsch T, Gnekow A, Kortmann RD et al (2000) Oral trofosfamide and etoposide in pediatric patients with glioblastoma multiforme. Cancer 89:2131\u20132137. doi :10.1002\/1097-0142(20001115)89:10<2131::AID-CNCR14>3.0.CO;2-J","journal-title":"Cancer"},{"key":"9662_CR39","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.bjc.6600552","volume":"87","author":"JE Wolff","year":"2002","unstructured":"Wolff JE, Westphal S, Molenkamp G, Gnekow A, Warmuth-Metz M, Rating D et al (2002) Treatment of paediatric pontine glioma with oral trophosphamide and etoposide. Br J Cancer 87:945\u2013949. doi: 10.1038\/sj.bjc.6600552","journal-title":"Br J Cancer"},{"key":"9662_CR40","first-page":"3569","volume":"22","author":"JE Wolff","year":"2002","unstructured":"Wolff JE, Wagner S, Sindichakis M, Pietsch T, Gnekow A, Kortmann RD et al (2002) Simultaneous radiochemotherapy in pediatric patients with high-grade glioma: a phase I study. Anticancer Res 22:3569\u20133572","journal-title":"Anticancer Res"},{"key":"9662_CR41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-006-9147-8","volume":"79","author":"JE Wolff","year":"2006","unstructured":"Wolff JE, Wagner S, Reinert C, Gnekow A, Kortmann RD, Kuhl J et al (2006) Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neurooncol 79:315\u2013321. doi: 10.1007\/s11060-006-9147-8","journal-title":"J Neurooncol"},{"issue":"2","key":"9662_CR42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11060-007-9495-z","volume":"87","author":"JE Wolff","year":"2006","unstructured":"Wolff JE, Classen CF, Wagner S, Kortmann RD, Palla SL, Pietsch T, K\u00fchl J, Gnekow A, Kramm CM (2008) Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database. J Neurooncol 87(2):155\u2013164","journal-title":"J Neurooncol"},{"key":"9662_CR43","first-page":"3773","volume":"26","author":"CM Kramm","year":"2006","unstructured":"Kramm CM, Wagner S, Van Gool S, Schmid H, Strater R, Gnekow A et al (2006) Improved survival after gross total resection of malignant gliomas in pediatric patients from the HIT-GBM studies. Anticancer Res 26:3773\u20133779","journal-title":"Anticancer Res"},{"key":"9662_CR44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11060-004-3546-5","volume":"72","author":"M Benesch","year":"2005","unstructured":"Benesch M, Wagner S, Berthold F, Wolff JE (2005) Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH). J Neurooncol 72:179\u2013183. doi: 10.1007\/s11060-004-3546-5","journal-title":"J Neurooncol"},{"key":"9662_CR45","first-page":"755","volume":"38","author":"HA Spiller","year":"2000","unstructured":"Spiller HA, Krenzelok EP, Klein-Schwartz W, Winter ML, Weber JA, Sollee DR et al (2000) Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. J Toxicol 38:755\u2013760","journal-title":"J Toxicol"},{"key":"9662_CR46","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1111\/j.1528-1167.2006.00846.x","volume":"47","author":"SA Koenig","year":"2006","unstructured":"Koenig SA, Buesing D, Longin E, Oehring R, Haussermann P, Kluger G et al (2006) Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 47:2027\u20132031. doi: 10.1111\/j.1528-1167.2006.00846.x","journal-title":"Epilepsia"},{"key":"9662_CR47","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1212\/WNL.56.10.1405","volume":"56","author":"TP Bohan","year":"2001","unstructured":"Bohan TP, Helton E, McDonald I, Konig S, Gazitt S, Sugimoto T et al (2001) Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 56:1405\u20131409","journal-title":"Neurology"},{"key":"9662_CR48","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11060-006-9133-1","volume":"79","author":"S Wagner","year":"2006","unstructured":"Wagner S, Warmuth-Metz M, Emser A, Gnekow AK, Strater R, Rutkowski S et al (2006) Treatment options in childhood pontine gliomas. J Neurooncol 79:281\u2013287. doi: 10.1007\/s11060-006-9133-1","journal-title":"J Neurooncol"},{"key":"9662_CR49","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ijc.20774","volume":"114","author":"K Camphausen","year":"2005","unstructured":"Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA et al (2005) Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 114:380\u2013386. doi: 10.1002\/ijc.20774","journal-title":"Int J Cancer"},{"key":"9662_CR50","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1196\/annals.1378.082","volume":"1091","author":"D Zaskodova","year":"2006","unstructured":"Zaskodova D, Rezacova M, Vavrova J, Vokurkova D, Tichy A (2006) Effect of valproic acid, a histone deacetylase inhibitor, on cell death and molecular changes caused by low-dose irradiation. Ann N Y Acad Sci 1091:385\u2013398. doi: 10.1196\/annals.1378.082","journal-title":"Ann N Y Acad Sci"},{"key":"9662_CR51","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1158\/1535-7163.MCT-05-0194","volume":"4","author":"DC Marchion","year":"2005","unstructured":"Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN (2005) In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 4:1993\u20132000. doi: 10.1158\/1535-7163.MCT-05-0194","journal-title":"Mol Cancer Ther"},{"key":"9662_CR52","unstructured":"Masoudi A, Elopre M, Amini E, Nagel ME, Ater JL, Gopalakrishnan V, Wolff JEA (2008) Influence of Valproic acid on outcome of high-grade gliomas in children. AntiCancer Res (accepted)"},{"key":"9662_CR53","first-page":"2583","volume":"25","author":"S Wagner","year":"2005","unstructured":"Wagner S, Reinert C, Schmid HJ, Liebeskind AK, Jorch N, Langler A et al (2005) High-dose methotrexate prior to simultaneous radiochemotherapy in children with malignant high-grade gliomas. Anticancer Res 25:2583\u20132587","journal-title":"Anticancer Res"},{"key":"9662_CR54","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1600-0463.2006.apm_516.x","volume":"114","author":"S Wagner","year":"2006","unstructured":"Wagner S, Csatary CM, Gosztonyi G, Koch HC, Hartmann C, Peters O et al (2006) Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68\/H and oral valproic acid. APMIS 114:731\u2013743. doi: 10.1111\/j.1600-0463.2006.apm_516.x","journal-title":"APMIS"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-008-9662-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-008-9662-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-008-9662-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T12:08:50Z","timestamp":1588853330000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-008-9662-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,5]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["9662"],"URL":"https:\/\/doi.org\/10.1007\/s11060-008-9662-x","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,5]]}}}